Department of Urology, Inje University Haeundae Paik Hospital, Busan, Republic of Korea.
Department of Urology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Eur J Surg Oncol. 2021 Feb;47(2):470-476. doi: 10.1016/j.ejso.2020.06.016. Epub 2020 Jun 17.
It remains unclear whether a short warm ischemic time (WIT) improves long-term renal function after partial nephrectomy (PN) for patients with pre-existing chronic kidney disease (CKD). We evaluated renal function after PN according to WIT duration in patients with stage III CKD.
We identified 277 patients with stage III CKD who underwent PN during 2004-2017. Propensity score matching was used to created two matched groups of patients: Group A (WIT of <25 min) and Group B (WIT of ≥25 min). The outcomes of interest were longitudinal kidney function change, new-onset stage IV CKD (eGFR <30 mL/min/1.73 m) and overall survival.
The two matched groups contained 85 patients each. The median follow-up durations were 49 months in Group A and 42 months in Group B. The median pre-treatment eGFRs were 52.4 mL/min/1.73 m in Group A and 52.6 mL/min/1.73 m in Group B. There were no differences in kidney function between the two groups throughout the follow-up period (P > 0.05). The 5-year rates of new-onset stage IV CKD were not significantly different between Group A and Group B (8.2% vs. 7.1%), with no significant difference in the risk of developing stage IV CKD in Group A (vs. group B, hazard ratio: 0.527, 95% confidence interval: 0.183-1.521; P = 0.236). The 5-year overall survival rates were 90.3% for Group A and 96.2% for Group B (P = 0.549).
A short WIT was not associated with better postoperative kidney function or survival after PN in patients with stage III CKD.
对于患有慢性肾脏病(CKD)的患者,短时间的热缺血时间(WIT)是否能改善部分肾切除术(PN)后的长期肾功能仍不清楚。我们根据 WIT 持续时间评估了 III 期 CKD 患者的 PN 后肾功能。
我们确定了 2004 年至 2017 年间接受 PN 的 277 例 III 期 CKD 患者。采用倾向评分匹配法创建了两组匹配的患者:A 组(WIT<25 分钟)和 B 组(WIT≥25 分钟)。关注的结局是纵向肾功能变化、新发 IV 期 CKD(eGFR<30ml/min/1.73m)和总体生存率。
两组匹配患者各 85 例。A 组中位随访时间为 49 个月,B 组为 42 个月。A 组治疗前 eGFR 中位数为 52.4ml/min/1.73m,B 组为 52.6ml/min/1.73m。两组在整个随访期间肾功能无差异(P>0.05)。A 组和 B 组的 5 年新发 IV 期 CKD 发生率无显著差异(8.2%比 7.1%),A 组发生 IV 期 CKD 的风险无显著差异(与 B 组相比,风险比:0.527,95%置信区间:0.183-1.521;P=0.236)。A 组 5 年总体生存率为 90.3%,B 组为 96.2%(P=0.549)。
对于 III 期 CKD 患者,短 WIT 与 PN 后术后肾功能或生存改善无关。